Safety Questions

In Phase 2 clinical trials, the most commonly reported side effects were gastrointestinal in nature: nausea, diarrhea, vomiting, constipation, and decreased appetite. These effects are consistent with the known pharmacology of GLP-1 receptor agonists and were predominantly mild to moderate in severity. Most GI events occurred during the dose-escalation period and diminished over time as participants adapted to the medication.

In the 48-week Phase 2 obesity trial, 6% to 16% of participants in the retatrutide groups stopped treatment because of adverse events (16% at 12 mg), against none on placebo. In the 68-week Phase 3 TRIUMPH-4 trial the rates were 4.0% with placebo, 12.2% with 9 mg and 18.2% with 12 mg. In the 80-week TRIUMPH-1 trial they were 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg), against 4.9% on placebo. Gastrointestinal events were the most common reason. For comparison, the US labels report 6.8% for semaglutide 2.4 mg and up to 6.7% for tirzepatide. In Phase 2, starting at 2 mg rather than 4 mg lowered nausea.

In the Phase 2 obesity trial (participants without diabetes), no significant hypoglycemia was reported. In the type 2 diabetes trial, hypoglycemia rates were low and were primarily associated with concomitant use of other diabetes medications (such as sulfonylureas) that can independently cause low blood sugar. Retatrutide's insulin-promoting effects are glucose-dependent, meaning they are activated mainly when blood sugar is elevated, which inherently reduces hypoglycemia risk.

Retatrutide raises heart rate, a known effect of GLP-1 receptor agonists. In the Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and then declined; the authors described the increases as similar to those reported for GLP-1 receptor agonists. Blood pressure and lipid profiles improved with treatment, which are favorable cardiovascular signals. However, no dedicated cardiovascular outcomes trial has been completed for retatrutide, so definitive cardiovascular safety or benefit data are not yet available.

The longest treatment durations reported so far are 80 weeks in the Phase 3 TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 trials and in TRANSCEND-T2D-2, with a 104-week extension in a TRIUMPH-1 subgroup. Long-term safety data over multiple years, which are essential for a medication intended for chronic use, will be generated by the broader Phase 3 TRIUMPH program and post-marketing surveillance if the drug is approved. Long-term effects on bone density, muscle mass, nutritional status, and organ function require continued study.

No unexpected serious safety signals were reported in the Phase 2 retatrutide trials. However, Phase 3 TRIUMPH-4 data (December 2025) identified a new signal: dysesthesia (abnormal skin sensations such as tingling, numbness or burning), reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group, compared with 0.7% for placebo. This signal was not prominent in Phase 2 data and is thought to be linked to glucagon receptor activity. Later Phase 3 trials reported lower rates at 12 mg: 12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2 and 6.4% in TRIUMPH-3. Dysesthesia was generally mild and infrequently led to discontinuation. The broader safety profile remains consistent with the known effects of incretin-based therapies, though Phase 3 trials with larger populations continue to provide a more comprehensive safety assessment.